Back to top

medical: Archive

Mark Vickery

Top Research Reports for SAP, Novo Nordisk & Thermo Fisher

SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.

NVOPositive Net Change TMONegative Net Change SAPPositive Net Change PSXPositive Net Change CGPositive Net Change HUBSPositive Net Change HURCNegative Net Change FONRNegative Net Change

Zacks Equity Research

PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study

Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.

AGENPositive Net Change AMRNPositive Net Change PROKPositive Net Change

Zacks Equity Research

Brookdale's Occupancy Registers a Rise to 80.5% in June 2025

BKD's June occupancy improves 230 bps year over year to 80.5%, driven by stronger move-ins and move-out activity across its senior living communities.

BKDPositive Net Change ADUSPositive Net Change MEDPNegative Net Change HIMSPositive Net Change

Zacks Equity Research

AMN Stock Gains Post Latest Deals With symplr to Boost Operations

AMN Healthcare sells Smart Square to symplr for $75 million and forms a new technology partnership aimed at boosting scheduling efficiency.

BSXPositive Net Change CORPositive Net Change AMNNegative Net Change ITGRPositive Net Change

Zacks Equity Research

Here's Why You Should Add PacBio Stock to Your Portfolio Now

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.

CORPositive Net Change PACBNegative Net Change ITGRPositive Net Change HIMSPositive Net Change

Zacks Equity Research

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program

Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.

BAYRYPositive Net Change VRNAPositive Net Change RXRXPositive Net Change RLYBNegative Net Change

Harshit Gupta

Veeva Expands Market Reach Through Targeted Strategic Partnerships

VEEV gains momentum in 2025 with strategic partnerships fueling growth in AI, clinical research, and compliance.

ORCLPositive Net Change VEEVPositive Net Change IQVNegative Net Change

Ahan Chakraborty

Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.

NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change

Zacks Equity Research

Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.

RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change

Zacks Equity Research

Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck

VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.

SNYPositive Net Change MRKPositive Net Change LLYPositive Net Change VRNAPositive Net Change

Zacks Equity Research

Alcon Stock Gains Following UNITY VCS' Approval in Canada

ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.

ABTNegative Net Change ALGNPositive Net Change ALCNegative Net Change CORPositive Net Change

Zacks Equity Research

Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?

TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.

TMONegative Net Change CAHNegative Net Change CORPositive Net Change PAHCPositive Net Change

Nilanjan Choudhury

Invest in 4 Winning Stocks With Proven Relative Price Power

DELL, JBL, PAHC, and HBM are showing strong relative price strength and upward earnings estimates amid a rising market.

DELLPositive Net Change JBLNegative Net Change HBMNegative Net Change PAHCPositive Net Change

Zacks Equity Research

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.

JNJPositive Net Change ALCNegative Net Change GKOSPositive Net Change SGHTNegative Net Change

Moumi Mondal

Is CVS Moving Closer to Reaching Its Long-Term Low 3X Leverage Goal?

CVS Health inches closer to its long-term leverage target, helped by Aetna margin recovery and disciplined cash use.

UNHNegative Net Change CINegative Net Change CVSNegative Net Change

Zacks Equity Research

Is the Options Market Predicting a Spike in AdaptHealth Stock?

Investors need to pay close attention to AHCO stock based on the movements in the options market lately.

AHCONegative Net Change

Mark Vickery

Top Analyst Reports for T-Mobile, AstraZeneca & Comcast

TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.

AZNPositive Net Change ETRPositive Net Change CMCSANegative Net Change UHSPositive Net Change ALGNPositive Net Change TMUSNegative Net Change

Ethan Feller

2 Small-Cap Stocks That Appear Ready to Surge (STKS, LGCY)

The ONE Group Hospitality and Legacy Education Inc. stocks boast a compelling mix is strong growth forecasts, reasonable valuations and improving analyst sentiment

LGCYPositive Net Change STKSPositive Net Change

Harshit Gupta

VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?

Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.

VEEVPositive Net Change IQVNegative Net Change HCATNegative Net Change CERTPositive Net Change

Zacks Equity Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

BAYRYPositive Net Change COGTPositive Net Change VRNAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

BAYRYPositive Net Change MBIOPositive Net Change VRNAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review

Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.

SNYPositive Net Change BIIBNegative Net Change DNLIPositive Net Change

Zacks Equity Research

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change

Kaibalya Pravo Dey

Healthcare Hit Again: Molina Cuts Guidance, Echoing Centene and UNH

MOH slashes 2025 EPS outlook by more than 10%, citing rising medical costs and echoing warnings from CNC and UnitedHealth.

UNHNegative Net Change MOHPositive Net Change CNCPositive Net Change

Moumi Mondal

Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?

HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.

ABTNegative Net Change HOLXPositive Net Change QGENPositive Net Change